New York: An early-stage human trial has found an experimental Ebola vaccine safe and it also elicited robust antibody responses in all 40 of the healthy adults who received it.

A report describing preliminary results of the study that tested the candidate vaccine called VSV-ZEBOV appeared online in The New England Journal of Medicine."The prompt, dose-dependent production of high levels of antibodies following a single injection and the overall favourable safety profile of this vaccine make VSV-ZEBOV a promising candidate that might be particularly useful in outbreak interventions," said one of the lead investigators Richard Davey from National Institute of Allergy and Infectious Diseases (NIAID) in the US.